XBiotech Inc. (NASDAQ:XBIT - Get Free Report) passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $3.17 and traded as low as $2.80. XBiotech shares last traded at $2.87, with a volume of 37,766 shares changing hands.
XBiotech Price Performance
The business's 50 day moving average price is $3.16 and its 200 day moving average price is $4.57. The firm has a market cap of $86.74 million, a PE ratio of -2.63 and a beta of 0.98.
XBiotech (NASDAQ:XBIT - Get Free Report) last posted its quarterly earnings data on Tuesday, March 18th. The biopharmaceutical company reported ($0.34) EPS for the quarter.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Deutsche Bank AG acquired a new position in XBiotech during the fourth quarter worth about $120,000. Northern Trust Corp boosted its holdings in shares of XBiotech by 15.2% during the 4th quarter. Northern Trust Corp now owns 211,476 shares of the biopharmaceutical company's stock worth $835,000 after purchasing an additional 27,909 shares during the last quarter. Geode Capital Management LLC grew its position in shares of XBiotech by 5.1% in the third quarter. Geode Capital Management LLC now owns 452,264 shares of the biopharmaceutical company's stock valued at $3,496,000 after purchasing an additional 22,059 shares in the last quarter. Barclays PLC increased its holdings in shares of XBiotech by 247.4% in the third quarter. Barclays PLC now owns 26,343 shares of the biopharmaceutical company's stock valued at $204,000 after purchasing an additional 18,761 shares during the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of XBiotech in the fourth quarter valued at approximately $58,000. Hedge funds and other institutional investors own 55.70% of the company's stock.
XBiotech Company Profile
(
Get Free Report)
XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.
Recommended Stories
Before you consider XBiotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and XBiotech wasn't on the list.
While XBiotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.